Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine +

Theralase(R) Releases Q1 2026 Financial Statements

Theralase Confirms Bladder Cancer Efficacy Ahead of FDA Filing; Dilution Concerns Weigh on Shares

By The Northwire Desk — AI Analysis May 29, 2026 · 17:05 TLT · 0.225 Theralase Technologies Inc.
Executive Summary
  • Q1 2026 Financial Performance: The company reported a net loss of $1,031,785 CAD and revenue increase to $132,634 CAD (up 45% year-over-year). Administrative expenses decreased by 16%, while R&D expenses dropped significantly by 36%.
  • Clinical Study II Results: Interim clinical data for BCG-Unresponsive NMIBC CIS shows a Complete Response rate of 65.2% among evaluable patients, with 40.4% maintaining response at 12 months. Safety profile remains favorable with no study-related Serious Adverse Events (SAEs).
  • Regulatory Strategy: The company intends to submit New Drug Applications (NDA) to Health Canada and the FDA in Q3 2026, with regulatory decisions anticipated in H1 2027.
  • Strategic Partnership: Reiteration of the collaborative agreement with Ferring Pharmaceuticals entered into January 2026 to expand Phase II NMIBC program via a new cohort evaluating Ruvidar® in combination with Adstiladrin®.
  • Financing Context: The financial release follows the May 20, 2026 closing of a $4.76 million private placement at $0.24 per unit to fund clinical studies and working capital.
Material Impact
  • Clinical Data Validation: The Q1 report confirms interim data released in March/April 2026 (65% CR rate). While positive, this is not a surprise as the market has been pricing in Study II success since enrollment completion in February 2026. It validates the NDA filing timeline rather than introducing new upside catalysts.
  • Financial Runway: The $1M quarterly burn rate implies an annualized loss of ~$4M. With only $4.76M raised in May, the company has approximately 12 months of runway assuming no further dilution, which is tight given the H1 2027 regulatory decision timeline.
  • Dilution Impact: The recent financing at $0.24 (current price $0.23) indicates significant equity dilution to fund operations. This caps immediate upside potential as new shares enter circulation.
  • Partnership Value: The Ferring collaboration is a strategic asset but does not provide upfront cash; it relies on future milestones and royalties, which are distant given the 2027 approval target.
  • Overall Materiality: The news confirms execution of the business plan without exceeding expectations. It mitigates risk regarding clinical failure but highlights capital structure risks due to burn rate and dilution.
TLT · Price
Company Overview
  • Company: Theralase Technologies Inc. is a biotechnology company focused on light-activated drugs for cancer and viral infections.
  • Flagship Project (Ruvidar®): A light-activated small molecule drug designed to treat non-muscle invasive bladder cancer (NMIBC) Carcinoma In Situ (CIS). It requires activation by the TLC-3200 Medical Laser System.
  • Secondary Project (Rutherrin®): An X-ray activated ruthenium-based compound for muscle-invasive bladder cancer and other solid tumors (brain, lung, pancreatic). Preclinical data shows high efficacy in mouse models.
  • Device Division: Develops the laser systems required to activate Ruvidar®, creating a potential hardware revenue stream alongside drug licensing.
Read the original news release →

More from Theralase Technologies Inc.

May 20, 2026 · 11:07

Theralase Secures Runway for Q3 Regulatory Filing Amidst Dilution Concerns

Financings May 05, 2026 · 19:11

Theralase Secures Runway Amidst Dilution Concerns and Revenue Decline

Financings May 04, 2026 · 17:23

Theralase Confirms Bladder Cancer Submission Timeline Amidst Continued Burn Rate

Earnings Apr 13, 2026 · 07:01

Theralase Preclinical Data Confirms Earlier Findings as Capital Runway Extends

Other Apr 10, 2026 · 07:01

Theralase Secures Runway for Regulatory Filing Amidst Dilutive Financing

Financings Mar 17, 2026 · 07:02

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Other